272 related articles for article (PubMed ID: 35305210)
21. Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic.
Rose DB; Nellesen D; Neary MP; Cai B
J Med Econ; 2017 Apr; 20(4):395-404. PubMed ID: 27981858
[TBL] [Abstract][Full Text] [Related]
22. Pathways Impacted by Genomic Alterations in Pulmonary Carcinoid Tumors.
Asiedu MK; Thomas CF; Dong J; Schulte SC; Khadka P; Sun Z; Kosari F; Jen J; Molina J; Vasmatzis G; Kuang R; Aubry MC; Yang P; Wigle DA
Clin Cancer Res; 2018 Apr; 24(7):1691-1704. PubMed ID: 29351916
[No Abstract] [Full Text] [Related]
23. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC
Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic options in lung neuroendocrine tumors: between established concepts and new hopes.
Brighi N; Lamberti G; Manuzzi L; Maggio I; Campana D
Anticancer Drugs; 2019 Aug; 30(7):e0784. PubMed ID: 30896503
[TBL] [Abstract][Full Text] [Related]
25. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours.
Scarpa A
Ann Endocrinol (Paris); 2019 Jun; 80(3):153-158. PubMed ID: 31072588
[TBL] [Abstract][Full Text] [Related]
26. Molecular alterations of neuroendocrine tumours of the lung.
Rossi G; Bertero L; Marchiò C; Papotti M
Histopathology; 2018 Jan; 72(1):142-152. PubMed ID: 29239031
[TBL] [Abstract][Full Text] [Related]
27. Specific Genomic Alterations in High-Grade Pulmonary Neuroendocrine Tumours with Carcinoid Morphology.
Cros J; Théou-Anton N; Gounant V; Nicolle R; Reyes C; Humez S; Hescot S; Thomas de Montpréville V; Guyétant S; Scoazec JY; Guyard A; de Mestier L; Brosseau S; Mordant P; Castier Y; Gentien D; Ruszniewski P; Zalcman G; Couvelard A; Cazes A
Neuroendocrinology; 2021; 111(1-2):158-169. PubMed ID: 32015233
[TBL] [Abstract][Full Text] [Related]
28. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
Zanini S; Renzi S; Giovinazzo F; Bermano G
Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
[TBL] [Abstract][Full Text] [Related]
29. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.
Hou J; Lambers M; den Hamer B; den Bakker MA; Hoogsteden HC; Grosveld F; Hegmans J; Aerts J; Philipsen S
J Thorac Oncol; 2012 Jan; 7(1):105-14. PubMed ID: 22134068
[TBL] [Abstract][Full Text] [Related]
30. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
Bago-Horvath Z; Sieghart W; Grusch M; Lackner A; Hayden H; Pirker C; Komina O; Węsierska-Gądek J; Haitel A; Filipits M; Berger W; Schmid K
Neuroendocrinology; 2012; 96(3):228-37. PubMed ID: 22378048
[TBL] [Abstract][Full Text] [Related]
31. Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets.
Capdevila J; Meeker A; García-Carbonero R; Pietras K; Astudillo A; Casanovas O; Scarpa A
Cancer Metastasis Rev; 2014 Mar; 33(1):345-51. PubMed ID: 24375391
[TBL] [Abstract][Full Text] [Related]
32. Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study.
Pivonello C; Rousaki P; Negri M; Sarnataro M; Napolitano M; Marino FZ; Patalano R; De Martino MC; Sciammarella C; Faggiano A; Rocco G; Franco R; Kaltsas GA; Colao A; Pivonello R
Endocrine; 2017 Jun; 56(3):603-620. PubMed ID: 27688013
[TBL] [Abstract][Full Text] [Related]
33. Molecular Pathology of Well-Differentiated Pulmonary and Thymic Neuroendocrine Tumors: What Do Pathologists Need to Know?
Volante M; Mete O; Pelosi G; Roden AC; Speel EJM; Uccella S
Endocr Pathol; 2021 Mar; 32(1):154-168. PubMed ID: 33641055
[TBL] [Abstract][Full Text] [Related]
34. Novel therapeutic approaches and mechanisms in neuroendocrine tumors: the role of targeted agents.
Papaxoinis G; Syrigos K; Saif MW
Discov Med; 2016 May; 21(117):391-402. PubMed ID: 27355335
[TBL] [Abstract][Full Text] [Related]
35. Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.
Vandamme T; Beyens M; de Beeck KO; Dogan F; van Koetsveld PM; Pauwels P; Mortier G; Vangestel C; de Herder W; Van Camp G; Peeters M; Hofland LJ
Br J Cancer; 2016 Mar; 114(6):650-8. PubMed ID: 26978006
[TBL] [Abstract][Full Text] [Related]
36. [Genomics of neuroendocrine tumors of the lung and gastrointestinal tract: similarities and differences].
Tímár J; Patócs A
Magy Onkol; 2018 Jul; 62(2):77-82. PubMed ID: 30027934
[TBL] [Abstract][Full Text] [Related]
37. Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung.
Righi L; Volante M; Rapa I; Tavaglione V; Inzani F; Pelosi G; Papotti M
Endocr Relat Cancer; 2010 Dec; 17(4):977-87. PubMed ID: 20817788
[TBL] [Abstract][Full Text] [Related]
38. Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches.
Oberg K; Casanovas O; Castaño JP; Chung D; Delle Fave G; Denèfle P; Harris P; Khan MS; Kulke MH; Scarpa A; Tang LH; Wiedenmann B
Clin Cancer Res; 2013 Jun; 19(11):2842-9. PubMed ID: 23459719
[TBL] [Abstract][Full Text] [Related]
39. NETs: organ-related epigenetic derangements and potential clinical applications.
Cives M; Simone V; Rizzo FM; Silvestris F
Oncotarget; 2016 Aug; 7(35):57414-57429. PubMed ID: 27418145
[TBL] [Abstract][Full Text] [Related]
40. MEN1 gene mutation and reduced expression are associated with poor prognosis in pulmonary carcinoids.
Swarts DR; Scarpa A; Corbo V; Van Criekinge W; van Engeland M; Gatti G; Henfling ME; Papotti M; Perren A; Ramaekers FC; Speel EJ; Volante M
J Clin Endocrinol Metab; 2014 Feb; 99(2):E374-8. PubMed ID: 24276465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
